Styleguide

Colors

Primary colors

Primary
Primary Medium
Primary Light
Primary Lighter
Primary Lightest

Primary colors

Black
White
Grey
Grey Light

Typography

Headings

H1: Lorem ipsum dolor sit amet consectetur mauris.

H2: Lorem ipsum dolor sit amet consectetur mauris.

H3: Lorem ipsum dolor sit amet consectetur mauris.

H4: Lorem ipsum dolor sit amet consectetur mauris.

H5: Lorem ipsum dolor sit amet consectetur mauris.
H5: Lorem ipsum dolor sit amet consectetur mauris.
H6: Lorem ipsum dolor sit amet consectetur mauris.
H6: Lorem ipsum dolor sit amet consectetur mauris.

Paragraphs

Body: Amgen's largest investment in cancer immunotherapy research aims to expand the number of tumors that can be treated with BiTEĀ® antibodies (bispecific T cell engagers). Amgen has been developing and enhancing the BiTE platform since 2012.

Small: Amgen's largest investment in cancer immunotherapy research aims to expand the number of tumors that can be treated with BiTEĀ® antibodies (bispecific T cell engagers). Amgen has been developing and enhancing the BiTE platform since 2012.

Lists

In the past 5 years, Amgen:

  1. Bullet List: Gained the first regulatory approval for a BiTE antibody
    1. Sub-Bullet List: Advanced three more investigational BiTEs into clinical trials
    2. Sub-Bullet List: Advanced three more investigational BiTEs into clinical trials
  2. Bullet List: Gained the first regulatory approval for a BiTE antibody
  3. Bullet List: Gained the first regulatory approval for a BiTE antibody

Quote

Selectivity is a crucial factor in BiTE design, since T cells are the immune system's most potent weapon.

CTAs

Default

Inline

Toggle

Forms

System error message. Lorem ipsum.
System error message. Lorem ipsum.
System error message. Lorem ipsum.
System error message. Lorem ipsum.
System error message. Lorem ipsum.
System error message. Lorem ipsum.
System error message. Lorem ipsum.
System error message. Lorem ipsum.

Deep and Broad Experience

We helped invent the processes and tools that built the global biotech industry, turning it into a leading source of therapies for patients needing additional options.

Focus on Biology

Amgen is helping to solve fundamental mysteries of biology. Our deep understanding of biological pathways has been the cornerstone of Amgen's scientific success. Our protein engineers are designing new molecular structures, employing nature's own building blocks to try to interdict disease and redefine what a medicine can accomplish.

State-of-the-Art Processes

No company has made a larger bet on using human genetics to drive R&D than Amgen.

Candidates with State-of-the-Art Processes

We're able to use our experience, processes and genetic assets to evaluate the quality of internal and external therapeutic candidates.

Subscribe for the latest from Amgen Science.

System error message. Lorem ipsum.
I authorize Amgen and its contractors to use my email address and provide me with updates, informational material, and/or contact me about Amgen Science. I understand that my email address will not be used for any other purposes. I understand that receiving these communications is optional and free and that I have the ability to opt out at anytime. For more information, please see the Amgen privacy policy.